COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Fundamental Analysis
USA - NASDAQ:COLL - US19459J1043 - Common Stock
45.34 USD
-0.64 (-1.39%)
45.34 USD
0 (0%)
Overall COLL gets a fundamental rating of 6 out of 10. We evaluated COLL against 192 industry peers in the Pharmaceuticals industry. While COLL belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on COLL. This makes COLL very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year COLL was profitable.
COLL had a positive operating cash flow in the past year.
COLL had positive earnings in 4 of the past 5 years.
In the past 5 years COLL always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of COLL (3.64%) is better than 84.38% of its industry peers.
With an excellent Return On Equity value of 21.27%, COLL belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
COLL has a better Return On Invested Capital (9.10%) than 87.50% of its industry peers.
The Average Return On Invested Capital over the past 3 years for COLL is below the industry average of 13.51%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROIC | 9.1% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
1.3 Margins
Looking at the Profit Margin, with a value of 7.72%, COLL belongs to the top of the industry, outperforming 83.85% of the companies in the same industry.
In the last couple of years the Profit Margin of COLL has declined.
With an excellent Operating Margin value of 20.74%, COLL belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
COLL's Operating Margin has improved in the last couple of years.
COLL has a better Gross Margin (57.22%) than 66.67% of its industry peers.
COLL's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% |
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so COLL is still creating some value.
COLL has less shares outstanding than it did 1 year ago.
COLL has less shares outstanding than it did 5 years ago.
COLL has a better debt/assets ratio than last year.
2.2 Solvency
COLL has an Altman-Z score of 1.46. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of COLL (1.46) is better than 61.98% of its industry peers.
The Debt to FCF ratio of COLL is 2.79, which is a good value as it means it would take COLL, 2.79 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.79, COLL belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
COLL has a Debt/Equity ratio of 2.71. This is a high value indicating a heavy dependency on external financing.
COLL has a worse Debt to Equity ratio (2.71) than 80.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 1.46 |
ROIC/WACC1.04
WACC8.77%
2.3 Liquidity
A Current Ratio of 1.36 indicates that COLL should not have too much problems paying its short term obligations.
COLL's Current ratio of 1.36 is on the low side compared to the rest of the industry. COLL is outperformed by 73.44% of its industry peers.
COLL has a Quick Ratio of 1.27. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.27, COLL is not doing good in the industry: 70.31% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
COLL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.73%, which is quite impressive.
Measured over the past years, COLL shows a very strong growth in Earnings Per Share. The EPS has been growing by 154.78% on average per year.
COLL shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.34%.
The Revenue has been growing by 16.31% on average over the past years. This is quite good.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
3.2 Future
Based on estimates for the next years, COLL will show a decrease in Earnings Per Share. The EPS will decrease by -2.05% on average per year.
Based on estimates for the next years, COLL will show a small growth in Revenue. The Revenue will grow by 3.11% on average per year.
EPS Next Y40.67%
EPS Next 2Y14.84%
EPS Next 3Y5.61%
EPS Next 5Y-2.05%
Revenue Next Year19.45%
Revenue Next 2Y11.07%
Revenue Next 3Y4.6%
Revenue Next 5Y3.11%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 6.31, the valuation of COLL can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 94.27% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 25.56. COLL is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 5.33, which indicates a rather cheap valuation of COLL.
COLL's Price/Forward Earnings ratio is rather cheap when compared to the industry. COLL is cheaper than 95.83% of the companies in the same industry.
COLL is valuated cheaply when we compare the Price/Forward Earnings ratio to 34.62, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.31 | ||
| Fwd PE | 5.33 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 97.92% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of COLL indicates a rather cheap valuation: COLL is cheaper than 94.79% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.94 | ||
| EV/EBITDA | 4.79 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of COLL may justify a higher PE ratio.
PEG (NY)0.16
PEG (5Y)N/A
EPS Next 2Y14.84%
EPS Next 3Y5.61%
5. Dividend
5.1 Amount
COLL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
45.34
-0.64 (-1.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners116.73%
Inst Owner Change0.4%
Ins Owners1.56%
Ins Owner Change-2.1%
Market Cap1.43B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.82
Price Target45.49 (0.33%)
Short Float %16.91%
Short Ratio13.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)0%
PT rev (3m)0.9%
EPS NQ rev (1m)1.52%
EPS NQ rev (3m)14.25%
EPS NY rev (1m)7.69%
EPS NY rev (3m)29.1%
Revenue NQ rev (1m)2.44%
Revenue NQ rev (3m)5.37%
Revenue NY rev (1m)-0.67%
Revenue NY rev (3m)0.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.31 | ||
| Fwd PE | 5.33 | ||
| P/S | 1.89 | ||
| P/FCF | 4.94 | ||
| P/OCF | 4.91 | ||
| P/B | 5.2 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.79 |
EPS(TTM)7.19
EY15.86%
EPS(NY)8.51
Fwd EY18.76%
FCF(TTM)9.18
FCFY20.26%
OCF(TTM)9.24
OCFY20.37%
SpS24.03
BVpS8.72
TBVpS-18.92
PEG (NY)0.16
PEG (5Y)N/A
Graham Number37.57
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROCE | 13.6% | ||
| ROIC | 9.1% | ||
| ROICexc | 12.09% | ||
| ROICexgc | N/A | ||
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% | ||
| FCFM | 38.21% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.94 | ||
| Cap/Depr | 0.72% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 2.17 | ||
| Cash Conversion | 75.92% | ||
| Profit Quality | 495.01% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | 1.46 |
F-Score7
WACC8.77%
ROIC/WACC1.04
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y40.67%
EPS Next 2Y14.84%
EPS Next 3Y5.61%
EPS Next 5Y-2.05%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year19.45%
Revenue Next 2Y11.07%
Revenue Next 3Y4.6%
Revenue Next 5Y3.11%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year149%
EBIT Next 3Y27.45%
EBIT Next 5Y16.73%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to COLL.
Can you provide the valuation status for COLLEGIUM PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.
What is the profitability of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 7 / 10.
Can you provide the financial health for COLL stock?
The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.